BioMarin Pharmaceutical underwent reiteration of rating by Wedbush

BioMarin Pharmaceutical

According to a report published by 24/1 WallStreet, research experts at Wedbush reiterated the ‘outperform’ rating of the stock of BioMarin Pharmaceutical in a research memo delivered to investors on the 10th of July. Currently, they have about $128.00 price objective on BioMarin Pharmaceutical’s stock.

The price target established by Wedbush implies a possible raise of 64.44% from the stock’s recent close.

Relating to the stock, various other equities experts have also issued research memos. BioMarin Pharmaceutical’s shares were given a $120.00 pro-ice objective by Robert W. Baird. Robert W. Baird also, on the 26th of April in a research note, gave BioMarin Pharmaceutical a ‘buy’ rating. In a research note, on the 21st of March, ValuEngine downgraded its BioMarin Pharmaceutical shares to a ‘hold’ rating, from a ‘buy’ rating. In a research note, on the 9th of April, Raymond James analyst Reni Benjamin resumes coverage on BioMarin Pharmaceutical Inc. with an ‘outperform’ rating and a price target of $110.00. In a research note, on the 7th of May, TheStreet downgraded its BioMarin Pharmaceutical shares to a‘d+’ (used to be ‘c+’). In a research note, on the 26th of April, BioMarin Pharmaceutical share’s ‘buy’ rating was reiterated by Cantor Fitzgerald and their target price was set to $131.00. 2 equities research experts have rated the BioMarin Pharmaceutical stock with a ‘sell’ rating. 4 equities research experts have issued the rating of ‘hold’. 13 equities research experts have given the BioMarin Pharmaceutical stock a ‘buy’ rating. Presently, the BioMarin Pharmaceutical holds a consensus rating of ‘Buy’. Its average price target is $115.54.

The debt-to-equity ratio of BMRN is 0.28. It holds a quick ratio of 2.76, and a current ratio of 3.83.